Overview

A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab

Status:
Terminated

Trial end date:
2011-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the value of adding IMC-A12 to irinotecan and cetuximab in participants with metastatic colorectal cancer (CRC).

Phase:

Phase 2

Details

Lead Sponsor:

Eli Lilly and Company
ImClone LLC

Collaborator:

NSABP Foundation Inc

Treatments:

Antibodies, Monoclonal
Bevacizumab
Camptothecin
Cetuximab
Irinotecan
Oxaliplatin